美国安进的地舒单抗可用于治疗什么病症？

It is seen as one of the most important growth drivers for Amgen, the world's largest biotechnology company. Desosumab is an injectable drug with the chemical name denosumab. Let’s learn about what diseases Amgen’s denosumab can be used to treat?

On May 27, 2019, denosumab was approved by the National Medical Products Administration for the treatment of giant cell tumor of bone that is unresectable or whose surgical resection may cause severe functional disability, including adults and adolescent patients with skeletal maturity (defined as at least 1 mature long bone and body weight >45 kg).

Indications of denosumab: (1) Bone metastases from solid tumors: It is suitable for preventing bone-related events in patients with bone metastases from solid tumors. (2) Important limitations of use: Not suitable for prevention of bone-related events in patients with multiple myeloma.

Amgen is principally engaged in the discovery, development, production and sales of innovative drugs for human use, and is committed to exploring the potential of biotechnology for the treatment of patients with serious diseases. As a leader in the global biopharmaceutical industry, Guizhou has strong R&D capabilities and product advantages. It insists on developing in the field of biotechnology for disease treatment. Its main fields include human genome, cancer, neuroscience and small molecule chemistry.

Desosumab has a high affinity with RANKL, preventing RANK ligands from activating RANK on the surface of osteoclasts, inhibiting osteoclast activation and development, and reducing bone resorption. Desosumab can also increase the bone density and bone strength of both cortical bone and trabecular bone, promote bone reconstruction, and reduce the incidence of vertebral, non-vertebral and hip fractures in postmenopausal osteoporotic women.

It is easy to use and can be injected subcutaneously by the patient at 60 mg/time with an interval of 6 months. While being treated with this drug, patients need to take 1000mg of calcium and at least 4001U of vitamin D every day. It is worth noting that unlike bisphosphonates, which have longer-term effects, denosumab does not bind to its receptors for long-term retention.